44 articles
The checked evidence shows two AI-in-finance developments: a startup raising $35M to verify AI agents' identities, and a Japanese internet group raising guidance on AI-driven gains. Robinhood's SEC-verified financials supply the market-side context. Source reliability is mixed, and we flag where.
Salesforce, ServiceNow and Confluent are all rebuilding around AI agents and shared data layers. The checked record shows the spending is going to governance and plumbing, while a Norwest investor warns AI shouldn't do finance maths. Smaller results are far more uneven.
Robinhood's event-contract revenue rose more than sixfold to $173M in Q3 while the CFTC sued Utah and Nasdaq planned a 23-hour day. Meanwhile Baselayer raised $35M to verify AI agents. We checked the Robinhood figures against SEC filings, and we flag where sources diverge.
AstraZeneca says proprietary data is its edge in AI-driven biologics design, and admits safety prediction is among the hardest unsolved problems. Summit's checked SEC figures show what an unproven-revenue oncology bet costs. The sources behind the AI pitch score poorly on our reliability checks.
Baselayer raised $35M to verify AI agents just as exchanges plan near-continuous trading and Robinhood's event-contract revenue grew more than sixfold to $173M. Figures come from SEC filings and cited sources, with source reliability and one data discrepancy noted.
Nasdaq plans a 23-hour trading day, Cboe and Robinhood plan company-specific KPI contracts, and startups are building identity checks for AI agents. We trace each claim to its source and flag where the evidence is thin or the sources disagree.
Micron's capital spending roughly doubled in a year, and Nvidia is co-developing memory to secure supply. Via News checked the figures against SEC filings and graded the sources. The sources behind several headline claims are weaker than the SEC-backed numbers.
Fintech money is moving toward identity and payments for AI agents, led by Baselayer's $35M Series A. One investor warns that AI should not do the maths. Via News checked the claims: Robinhood's SEC-filed figures anchor the picture, and the thin evidence is flagged.
As trading moves toward 23-hour days and retail event contracts, a startup is raising $35M to verify the AI agents that may transact in them, while a Norwest investor says AI shouldn't do finance maths. Figures here come from fidelity-checked SEC data and named, dated sources.
Radical Numerics says AI-designed viruses have treated its first patient, the clearest AI-therapeutics milestone in a crowded late-2026 biotech news cycle. The claim is unverified, so we set it against audited Incyte figures and checked trial and royalty data.
In Q3 2026 earnings calls, Lam Research's CFO guided to $8.6B of December-quarter revenue and said supply chains were the limit on AI-driven chip demand. Dow and Union Pacific talked cost cuts and fuel. We checked Dow's SEC-filed numbers against what its CFO said.
Lam Research's CFO said the AI-driven chip-equipment boom is held back by supply chains, not demand. Dow and Union Pacific are cutting costs against high energy and fuel prices. This piece is built from Q3 2026 earnings-call transcripts and SEC-filed Dow figures.
Dow, Union Pacific and Rio Tinto are hitting profit targets with job cuts, fuel pass-throughs and volume, not AI. The agentic-AI case in this dossier is a vendor press release with no customer results. We cite SEC-checked Dow figures and the speakers' own words.
Dow and Union Pacific are meeting an energy-cost shock with internal cost programs and cash discipline, not growth bets. For AI watchers the dossier's verified evidence is thin: agentic AI shows up in vendor claims, not in these CFOs' results. Dow's SEC-checked history supplies the baseline.
Robinhood announced an 'agent' product and Cboe KPI contracts in the same week Baselayer raised $35M to verify AI agents. Robinhood's SEC-verified revenue has risen from $1.87B to $4.47B in two years. The dossier says nothing about what Robinhood Agent does, so this piece separates what is checked from what is not.
In the week of 15 to 20 October 2026, ServiceNow launched a signed credential for AI agents and Salesforce agreed to buy Braze. Both moves treat enforced control as the product. Figures here come from SEC-checked data and company releases, with source reliability noted.
Oncology reaches ESMO with regulatory wins and heavy antibody-drug conjugate (ADC) interest. For AI readers, the more telling story is the 'lab of the future' pitch, which is only stated intent, from a source whose claims did not check out. Summit's audited filings show what drug development costs.
Analysts upgraded Palantir on customer expansion and the finding that customer-built AI apps complement its platform. Partnerships ran from banking to sovereign AI. The stock still fell five sessions in a row, and J.P. Morgan was cautious on defense. Every claim here is tied to a named source.
AstraZeneca's Puja Sapra describes agentic, de novo biologics design and automated 'labs of the future'. The source documents no demonstrated result, and our checks found none of its 11 claims held up. Meanwhile, SEC-verified filings show what a late-stage oncology bet costs: Summit's FY2025 net loss was about five times FY2024's.
Analysts upgraded Palantir on a thesis that customer-built AI apps complement its platform. Partnerships in banking and sovereign AI followed, then a 7% one-day drop. J.P. Morgan is cautious on traditional defense names. Every claim below is traced to a named source, with reliability noted.